Panel: Pharma’s Big Bets and the Resurgence of M&A

Session details:

Patent cliffs worth hundreds of billions in revenue are forcing pharmaceutical giants to abandon their cautious M&A stance. After years of selective, smaller acquisitions, 2025 witnessed a return to transformative deal-making as competitive pressures intensified. Industry leaders will dissect the strategic drivers behind this shift and examine whether aggressive portfolio building can offset the looming revenue gaps that threaten sector stability.